Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study
- Authors
- Song, Hoo Rim; Bahk, Won-Myong; Woo, Young Sup; Jeong, Jong-Hyun; Kwon, Young-Joon; Seo, Jeong Seok; Kim, Won; Kim, Moon-Doo; Shin, Young-Chul; Lee, Sang-Yeol; Min, Kyung Joon
- Issue Date
- Aug-2015
- Publisher
- 대한정신약물학회
- Keywords
- Mirtazapine; Generic drugs; Efficacy; Tolerability
- Citation
- Clinical Psychopharmacology and Neuroscience, v.13, no.2, pp 144 - 149
- Pages
- 6
- Journal Title
- Clinical Psychopharmacology and Neuroscience
- Volume
- 13
- Number
- 2
- Start Page
- 144
- End Page
- 149
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/10424
- DOI
- 10.9758/cpn.2015.13.2.144
- ISSN
- 1738-1088
2093-4327
- Abstract
- Objective: Mirtax is a generic mirtazapine widely used since 2003. We conducted an open-label, uncontrolled 6-week study to evaluate the efficacy and safety of Mirtax for major depressive disorder (MDD). Methods: Ninety three MDD patients with the diagnosis of MDD and 17-item Hamilton Depression Rating Scale (HDRS) score >= 14 were recruited. The HDRS, Montgomery-Asberg Depression Rating Scale (MADRS), and the Clinical Global Impressions-Severity Scale (CGI-S) were administered at baseline, 1, 2, 4 and 6 weeks, Response (>= 50% decrease in the HDRS or MADRS score), remission (absolute HDRS score or MADRS score <= 10) and CGI-I score <= 2 were also calculated, Adverse event (AE) frequency and severity, weight, blood pressure, and pulse rate were checked to assess safety. Results: The starting dosage was 11.5+/-6.4 mg/day, and the maintenance dosage was 23.1+/-9.4 mg/day. During 6 weeks, HDRS, MADRS and CGI-S scores decreased from 25.1+/-5.6 to 11.9+/-8.6 (mean change -13.1+/-8.3, p<0.001), from 30.2+/-6.3 to 13.73+/-10.40 (mean change -16.5+/-9.8, p<0.001), and from 5.0+/-0.8 to 2.5+/-1.3 (mean change -2.5+/-1.3, p<0.001), respectively, The percentages of responders, remitters by HDRS and patients with a CGI-I score <= 2 were 64.6%, 35.4% and 52.7%, respectively. Significant decreases in HDRS, MADRS and CGI-S scores were confirmed at week 1, The total rate of AEs was 32.3%; the most frequently reported AEs were sedation (4.3%) and constipation (4,3%), Weight was increased from 58.8+/-10.6 to 60.3+/-9.3 kg (mean change 0.7+/-1.7 kg, p=0.004). Conclusion: This study, as the first clinical trial of generic mirtazapine, demonstrated the efficacy and tolerability of Mirtax for MDD using a single treatment design.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Psychiatry > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/10424)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.